Two experimental GHRH antagonist peptides successfully blocked growth hormone release from human pituitary adenoma tissue, providing the first direct evidence that these drugs could treat acromegaly when surgery isn't an option.
3-5x GH spike blockedGHRH antagonists completely prevented the 3- to 5-fold growth hormone elevation triggered by GHRH pulses in human adenoma cells
What the researchers found
GHRH antagonists MZ-4-71 and JV-1-36 effectively blocked GHRH-stimulated growth hormone secretion from human pituitary adenoma cells. When tumor cells were exposed to GHRH pulses, GH levels rose 3- to 5-fold above baseline. Both antagonists completely prevented this stimulatory response.
Importantly, neither GHRH antagonist affected baseline GH secretion, indicating the tumor cells were not producing GHRH themselves in an autocrine loop — they were responding to external GHRH signals. The somatostatin analog RC-160 showed similar inhibitory effects and was more potent than natural somatostatin-14. The study also confirmed abundant expression of the GHRH receptor and its splice variant SV1 in the adenoma tissue.
Why it matters
Acromegaly is currently treated with surgery and somatostatin analogs, but not all patients respond adequately. GHRH antagonists represent a fundamentally different approach — blocking the upstream signal that drives growth hormone overproduction rather than suppressing GH release at the somatostatin receptor. This study provided the missing proof that GHRH antagonists actually work on human pituitary adenoma tissue, not just in animal models.
How the study worked
Researchers obtained pituitary tumor tissue from a patient with a GH-secreting adenoma during surgery. They set up a superfusion system to test drug effects on living tumor cells. Using Western blot and immunohistochemistry, they confirmed the tumor expressed GHRH receptors. They then measured GH secretion in response to GHRH pulses alone, GHRH with GHRH antagonists, and GHRH with somatostatin or its analog RC-160.
What this study cannot tell us
This was an in vitro study using tissue from a single patient's tumor, so results may not generalize to all GH-secreting adenomas. The superfusion system, while useful for measuring acute hormone responses, doesn't replicate the complex in vivo environment. No dose-response data or IC50 values were reported in the abstract. The drugs tested are experimental and have not progressed to clinical trials for acromegaly.
How to read the evidence
This is an in vitro laboratory study using tissue from a single human tumor. It provides valuable mechanistic proof-of-concept but is far from clinical evidence. No in vivo human data exists for these GHRH antagonists in acromegaly.
When this study was published
Published in 2012, this study established an important proof-of-concept. GHRH antagonists remain an area of active research, though somatostatin analogs continue to dominate clinical acromegaly treatment.
The bigger picture
This study advances the field of peptide-based treatments for pituitary disorders. GHRH and its receptor system have long been studied as therapeutic targets, but clinical development of GHRH antagonists has lagged behind somatostatin analogs. This proof-of-concept on human tissue supports continued development of GHRH antagonists, particularly for acromegaly patients who don't respond well to existing somatostatin-based therapies. The GHRH receptor splice variant SV1 is also being investigated as a target in various cancers.
Questions still open
- Would GHRH antagonists provide additional benefit when combined with somatostatin analogs in patients with partially responsive acromegaly?
- Do all GH-secreting adenomas express sufficient GHRH receptor to respond to these antagonists, or is there heterogeneity?
- Could targeting the SV1 splice variant of the GHRH receptor offer more selective therapeutic effects?
Common questions
What is acromegaly and how is it currently treated?
How are GHRH antagonists different from somatostatin analogs?
Read the original research
Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue.
Neuroendocrinology, 96(1), 81-8
Citation
Szalontay, Luca; Benveniste, Ronald J; Schally, Andrew V; Vidaurre, Irving; Nadji, Mehrdad; Zarandi, Marta; Block, Norman L; Kovacs, Magdolna. (2012). Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue.. Neuroendocrinology, 96(1), 81-8. https://doi.org/10.1159/000335989